BND-35

• Description :

  BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model[1].

• UNSPSC :

  12352203

• Target :

  Transmembrane Glycoprotein

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• References & Citations :

  [1]Peretz T, et al. BND-35, a novel anti-ILT3 antibody for remodulation of the tumor microenvironment[J]. Cancer Research, 2024, 84 (6_Supplement) : 3920-3920.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  No Development Reported